2 August 2006 in BJU International
OBJECTIVE: To prospectively assess the outcome of patients treated according to the European Association of Urology (EAU) guidelines on the management of penile cancer, a system originally based on retrospective series. PATIENTS AND METHODS: Between 2002 and 2005, 100 consecutive patients (median age 62 years) with penile cancer were treated at one institution; all were categorized and treated according to EAU guidelines. Data were analysed using the z ‐test, with significance defined as P < 0.05. RESULTS: Survival curves were limited to those with >12 months of follow‐up (mean 29); the survival of the whole group was 92%. Of men with palpable nodes, 72% had lymph node involvement, whereas 18% of those with impalpable nodes who had lymphadenectomy according to the guidelines had lymph node disease. The grade of the primary tumour was more predictive than T stage for lymph node involvement and survival. The 3‐year disease‐specific survival for N0, N1 and N2 disease was 100%, 100% and 73%, respectively, and survival at 12 months for N3 disease was 67%. The median survival for those with metastases was 3 months. CONCLUSION: The overall survival of men with penile cancer is high, with a clear benefit for early lymphadenectomy in men with positive nodal disease. However, the current EAU guidelines are limited in predicting those patients with micrometastatic disease, with the result that 82% of patients undergo unnecessary prophylactic lymphadenectomy. There is a need to identify more accurate molecular markers for predicting lymph node disease, or the role of novel staging techniques must be assessed.
1 June 2020 in European Urology Oncology
1 July 2013 in BJU International
To compare the oncological safety of treating patients with penile cancer with conservative techniques developed to preserve function, cosmesis and psychological well‐being with more radical ablative strategies. We conducted an extensive review of the literature of penile‐preserving and ablative techniques and report on the oncological as well as functional outcomes. There were no randomised studies comparing penile‐preserving and ablative techniques. Most studies consisted of retrospective cohorts. The quality of evidence was level 3 at best. Cancer‐specific survival is similar in penile‐preserving and ablative approaches for low‐stage disease. Penile preservation is better for functional and cosmetic outcomes and should be offered as a primary treatment method in men with low‐stage penile cancer.
1 September 2000 in The Hematology Journal
1 July 2001 in Irish Journal of Medical Science (1971 -)
12 January 2022 in BJUI Compass
Objectives: To assess novel surgical techniques in management of Peyronie's disease.Subjects: Forty‐three men underwent corrective surgery using either partial plaque incision and nongraft (PPING) or multiple plaque incisions and graft (MPIG). The technique used was determined intra‐operatively. Patients were assessed at baseline and follow‐up based on Peyronie's disease questionnaire patient‐reported outcome measure (PDQ‐PROM) and erectile function.Results: The two groups were well matched in age and erectile function. At baseline MPIG group had greater deformity and poorer patient‐reported outcome. Penile curvature improved from 67.9° to 10.5° in the PPING group and 77.9° to 7.1° with MPIG. PDQ‐PROM improved from 29 to 13 in those who underwent PPING and 38.5 to 17.6 in those undergoing MPIG. Erectile function was preserved in both groups.Conclusions: These novel surgeries are effective in restoring penile shape and length while preserving erectile function. This is reflected in improved patient‐reported outcomes. These findings should be verified by multi‐institutional study.